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INTRODUCTION
Diabetic nephropathy is characterized by an expansion of
the glomerular mesangium, caused by mesangial cell prolif-
eration and an excessive accumulation of extracellar matrix
(ECM) proteins, eventually leading to glomerulosclerosis
and renal failure (1, 2). Glomerulosclerosis is one of the com-
plications associated with diabetes. Mesangial expansion
caused by cell proliferation and glomerular ECM accumula-
tion is one of the earliest renal abnormalities observed at the
onset of hyperglycemia in diabetes mellitus (3). Because
hyperglycemia is assumed to trigger the glomerulosclerosis
that results from an imbalance in the control of glomerular
mesangial cells proliferation (4), glomerular mesangial cells
cultured in high glucose medium have been used as a model
to study unbalanced gene expression in diabetes (5). High
levels of glucose induce the production of transforming growth
factor (TGF)- 1, plasminogen activator inhibitor (PAI)-1,
collagen, fibronectin, protein kinase C, collagen, matrix met-
alloprotein-2. It also increases the activities of transcription
factors such as NF- B, which regulate the transcription of
genes that are involved in glomerulosclerosis (6-8). Investi-
gations of glomerular mesangial cells and proximal tubular
cells have demonstrated that high glucose media induces the
enhanced expression of TGF- 1 mRNA and protein, the
biosynthesis of collagen and other ECM constituents (9-11).
TGF- 1 is a multifunctional cytokine that plays an impor-
tant role in wound healing, cell proliferation, differentiation,
apoptosis, immune response and ECM remodeling. TGF- 1
is a critical cytokine involved in diabetes-induced ECM in
both cell cultures and animal models of diabetic kidney dis-
ease. TGF- 1 plays a central role in tissue repair by stimulat-
ing the balanced expression of ECM such as collagen, fibro-
nectin and matrix proteoglycans. Thus suppression of TGF- 1
could be an effective strategy for the prevention of glomeru-
losclerosis.
RNAi, a process of sequence-specific gene suppression is
a known as a natural gene regulatory mechanism. Small inter-
fering RNAs (siRNAs) mediate RNAi, a process in which
target mRNAs are degraded. It has recently been reported
that siRNAs technology can be used to produce post-tran-
scriptional gene silencing in mammalian cells. The mecha-
nisms of RNAi have become more defined. When dsRNAs
are introduced into an organism, the sequence-specific destruc-
tion of endogenous target mRNAs occurs. This process in-
volves the cleavage of dsRNAs into active 21-23 nucleotide
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The Inhibitory Effect of siRNAs on The High Glucose-Induced 
Overexpression of TGF- 1 in Mesangial Cells
Diabetic nephropathy is characterized by an expansion of the glomerular mesangium,
caused by mesangial cell proliferation and an excessive accumulation of extracellar
matrix (ECM) proteins, which eventually leading to glomerulosclerosis. TGF- 1
was found to play an important role in the accumulation of ECM in the kidney. In this
study, TGF- 1 RNA interference was used as an effective therapeutic strategy. The
inhibitory effect of TGF- 1 small interfering RNAs (siRNAs) on the high glucose-in-
duced overexpression of TGF- 1 in rat mesangial ceys (RMCs). A high levels of glu-
cose induces TGF- 1 mRNA and protein, and TGF- 1 siRNAs reduce the ability
of high glucose to stimulate their expression. We also examined the inhibitory effect
of TGF- 1 siRNAs on the expression of plasminogen activator inhibitor (PAI)-1 and
Collagen Type I which are down-regulators of TGF- 1. The expression of TGF- 1,
PAI-1 and Collagen Type I was increased in RMCs that were stimulated by 30 mM
glucose. TGF- 1 siRNAs reduces high glucose-induced TGF- 1, PAI-1, and Col-
lagen Type I mRNA and protein expression in a dose-dependent manner. In conclu-
sion, the present study demonstrates that TGF- 1 siRNAs effectively inhibits TGF-1
mRNA and protein expression in RMCs. These suggest that TGF- 1 siRNAs thro-
ugh RNAi may be a useful tool for developing new therapeutic applications for the
treatment of diabetic nephropathy. 
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(nt) length siRNAs by Dicer (12) or another RNase III-like
enzyme (13). These siRNAs are incorporated into a RNAi-
induced silencing complex (14) and are then used as a guide
to degrade the corresponding mRNA (15).
The aim of the present study was to investigate the effect
of TGF- 1 siRNAs on the high glucose-induced overexpres-
sion of TGF- 1 in the rat mesangial cells (RMCs). We also
examined the inhibitory effect of TGF- 1 siRNAs on the
expression of PAI-1 and Collagen Type I which are down-
regulators of TGF- 1. We applied the TGF- 1 siRNAs
strategy to suppress the proliferation and gene expression of
RMCs induced by high glucose levels. 
MATERIALS AND METHODS
Selection of siRNAs for TGF- 1 and synthesis of TGF- 1
siRNAs
The selection of TGF- 1 siRNAs for TGF- 1 was per-
formed using the GenBank database BLAST program. The
sequences of siRNAs against rat TGF- 1 mRNA (GenBank,
accession TGF- 1 site NM_021578) are as follows:
5′ AACCAAGGAGACGGAATACAGttcaagagaCTGT-
ATTCCGTCTCCTTGGTTTTTTT-3′ . TGF- 1 siRNAs
sequences 9-mer insert of hairpin construction with siRNAs
consisting of 21-mer sense and antisense. The DNA frag-
ment was digested with EcoRI and XbaI, and then cloned
into the EcoRI and XbaI site of pUC-U6-extra. The 21-mer
TGF- 1 siRNAs were custom-synthesized by BIONEER
(Seoul, Korea). 
Cells culture 
RMCs were obtained from a culture of glomeruli isolated
from male Sprague-Dawley (SD) rats weighing 100 to 150 g
using differential sieving methods as described previously (16).
Isolated glomeruli were cultured in RPMI 1640 (GIBCO,
Grand Island, NY, U.S.A.) complete medium containing
100 U/mL penicillin, 100  g/mL streptomycin, 0.25  g/mL
amphotericin B, 10 mg/mL insulin, 6.7  g/L sodium selen-
ite, 5.5 mg/L transferrin, and 20% heat-inactivated fetal calf
serum (FCS; South Logan, UT, U.S.A.) at 37℃ in a humid-
ified 5% CO2 atmosphere. The identity of the RMCs were
confirmed by phase contrast microscopy according to the
morphologic criteria (stellate-shaped cell bodies with irreg-
ular cytoplasmic projections (17), RMCs from passage 10-
15 were used in the cell studies. 
Uptake and localization of fluorescein-labeled-TGF- 1
siRNAs
RMCs were seeded at 2×104 cells/well in 2-well cham-
ber slides and cultured in RPMI 1640 complete medium for
24 hr. The cells were serum-starved for 24 hr in RPMI 1640
containing 0.5% FBS and transfected with fluorescein-labeled-
TGF- 1 siRNAs. TGF- 1 siRNAs were labeled using the
Label IT Fluorescein Nucleic Acid Labeling Kit (Panvera,
Madison, WI, U.S.A.) were used to facilitate the transfection
of TGF- 1 siRNAs into RMCs. Briefly, 0.5  g of TGF- 1
siRNAs in DMEM (GIBCO, Grand Island, NY, U.S.A.) were
mixed with the Plus reagent and incubated at room temper-
ature for 15 min. The siRNAs were mixed with 2  g of Lipo-
fectamine Pluse Reagent and subsequently incubated at room
temperature for 15 min. The cells were washed with serum-
free DMEM and 0.03 mL/well of serum-free DMEM was
then added to the cells. The siRNAs-liposome complexes
were added drop by drop to each well and incubated at 37℃
for 24 hr. Finally, the RMCs were washed three times with
phosphate buffered saline (PBS) and fixed in methanol at 4℃
for 10 min. The cells were mounted and observed through a
fluorescence microscope. The effect of TGF- 1 siRNAs on
TGF- 1 mRNA expression in RMCs was investigated. 
Comparison of the effect of TGF- 1 siRNAs on the level
of TGF- 1, PAI-1 and collagen Type I protein
The cells were lysed in buffer (50 mM Tris, 150 mM NaCl,
5 mM EDTA, 0.5% NP-40, 100 mM PMSF, 1 M DTT, 10
g leupeptin, 10 g aprotinin (Sigma, St. Louis, MO, U.S.A.)
and centrifuged at 12,000 g for 10 min after storing them
on ice for 30 min. The protein content of the supernatants
was determined using the Bradford protein assay (BioRad,
Hercules, CA, U.S.A.) and boiled with 4×SDS sample buffer
for 10 min. 10 g of protein was loaded in each well of 8-12%
SDS-PAGE and electrophoresis was then performed at 15 V
for 12 hr. The proteins were transferred onto a nitrocellulose
filter and probed with TGF- 1, PAI-1 antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, U.S.A.), Collagen Type I
(Oncogene, Cambridge, MA, U.S.A.) followed by a secondary
antibody conjugated to horseradish peroxidase and detected
with enhanced chemiluminescence reagents (Amersham, Pis-
cataway, NJ, U.S.A.). 
Comparison of the effect of TGF- 1 siRNAs on the level
of TGF- 1, PAI-1 and collagen Type I mRNA
Total RNA was extracted from cultured RMCs with RNA-
zol B (TEL-TEST, Friendswood, TX, U.S.A.) according to
the manufacturer’s instructions. The purity and quantity of
the RNA preparation were determind by measuring the opti-
cal densities at 260 and 280 nm. Total RNA was reverse tran-
scribed with oligo-d (T) primers and M-MLV reverse tran-
scriptase (Promega, Madison, WI, U.S.A.). cDNA was ampli-
fied by PCR using primer sets specific to rat TGF- 1, PAI-1,
Collagen Type I and a constitutively expressed house keeping
gene, glyceraldehydes-3-phosphate-dehydrogenase (GAPDH)
as the control. The primers used for PCR areas follows: 432 H.-J. Noh, H.-C. Kim, S.-S. Lee, et al.
The reaction was run for 30 cycles with a cycling parame-
ter of 50 sec at 95℃, 60 sec at (TGF- 1: 60℃, PAI-1: 56℃
and Collagen Type I: 50℃), 60 sec at 72℃ PCR products
were visualized on a 1% agarose gel. The amounts of TGF-1 ,
PAI-1 and Collagen Type I mRNA were measured by den-
sitometry and expressed relative to the densities of GAPDH.
The effect of TGF- 1 siRNAs on RMCs proliferation
RMCs cultured in glucose at a normal concentration (5.5
mM) were removed from the culture flasks by incubation
with PBS containing 0.25% trypsin and 5 mM EDTA. Equal
numbers of cells were seeded on tissue culture plates. At 20-
50% confluence, the RMCs were rendered quiescent by incu-
bation for 24 hr in growth medium deficient in insulin and
serum. To evaluate the effect of TGF- 1 siRNAs on RMC
proliferation, Lipofectamin Plus Reagent: TGF- 1 siRNAs
(100 nM) was added to the wells, and the cells were incu-
bated at 37℃ for an additional 5 hr. After incubation, the
cells were exposed to medium containing 1% serum and
normal glucose (5.5 mM) or high glucose (30 mM). The index
of cell proliferation was determined with a WST cell count-
ing kit (Wako, Osaka, Japan) after 48 hr. 
Statistical analyses 
The data are presented as means±standard error. The sta-
tistical difference between means was determined using the
Student’s t-test; p<0.05 was considered significant. 
RESULTS
Overexpression of TGF- 1 mRNA by high glucose level
For the induction of TGF- 1 expression by high glucose
mesangial cells were exposed to 5.5 mM glucose, 20 mM
glucose, 30 mM glucose and 40 mM glucose in DMEM media
for 24 hr. TGF- 1 mRNA expression was determined by
RT-PCR. The expression level of TGF- 1 increased by about
1.8 fold in 30 mM glucose (Fig. 1). 
Uptake and localization of fluorescein-labeled-TGF- 1
siRNAs 
To determine the transfection efficiency of TGF- 1 siR-
NAs, fluorescein-labeled-TGF-siRNAs were transfected to
RMCs. The cells were then evaluated by fluorescence micro-
scopy. Most of the RMCs exhibited strong fluorescence in
the cytoplasm and nucleus (Fig. 2). 
The effect of TGF- 1 siRNAs on the level of TGF- 1,
PAI-1 and Type I collagen protein in high glucose-induced
RMCs 
To examine the possibility of dose dependence in the sup-
pression effects of TGF- 1 siRNAs (2, 4, and 8  g) on the
protein expression of TGF- 1, PAI-1 and Collagen Type I,
they were transfected into primary cultured RMCs. Transla-
tional expression was confirmed by Western blot analysis
Rat TGF- 1 sense 5′ -CCTGCTGCTTTCTCCCT-
CAACC-3′
antisense 5′ -CTGGCACTGCTTCCCGA-
AATGTC-3′
Rat PAI-1 sense 5′ -CACGAGTACGACATCCT-
GGAA-3′
antisense 5′ -CCCTCTGAGCTCCACTT- 
CAGT-3′
Rat Collagen  sense 5′ -CTGACTGGAAGAGCGG- 
Type I AGAG-3 
antisense 5′ -TGAGTTTGGGTTGTTG- 
GTCT-3′
Rat GAPDH sense 5′ -GTGGACATTGTTGCCAT- 
CAACG-3′
antisense 5′ -GAGGGAGTTGTCATATT-
TCTCG-3′
TGF- 1 (598 bp)
5.5 20 30 40
Glucose 
(mM)
GAPDH (315 bp)
Fig. 1. TGF- 1 stimulated by 5.5, 20, 30 and 40 mM glucose in
RMCs. After incubation of RMCs with control (5.5 mM), high (20
mM), high (30 mM), high (40 mM) glucose for 24 hr, total RNA was
isolated, reverse transcripted and amplified by the polymerase
chain reaction (A). TGF- 1 levels for each conditions were mea-
sured by means of an LAS-3000 image analyzer (B). The expres-
sion level of TGF- 1 increases in 30 mM high glucose. 
Fig. 2. Fluorescence microscopy photograph of RMCs transfected
with TGF- 1 siRNAs in cationic liposomes. The fluorescein labeled
TGF- 1 siRNAs are transfected to RMCs (×200). 
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(Fig. 3A) and the result were measured by means of an LAS-
3000 image analyzer (Fig. 3B). Intracellular TGF- 1, PAI-
1 and Collagen Type I protein expressions were significantly
increased by about 1.6, 2.1, 1.6 fold by high levels of glu-
cose. Compared with the high glucose, transfection of TGF-1
siRNAs (2, 4, and 8  g) reduced TGF- 1, PAI-1 and Col-
lagen Type I protein levels in a dose-dependant manner. In
addition, the expression was significantly inhibited in cells
treated with TGF- 1 siRNAs (8  g).
The effect of TGF- 1 siRNAs on the level of TGF- 1,
PAI-1 and collagen Type I mRNA in high glucose-induced
RMCs 
To examine the possibility of dose dependence on the sup-
pression effects of TGF- 1 siRNAs (1, 2, and 4  g) on the
mRNA expression of TGF- 1, they were transfected into
primary cultured RMCs. Total RNA was isolated from the
transfected cells and RT-PCR was performed (Fig. 4A) and
the result were measured by means of an LAS-3000 image
analyzer (Fig. 4B). Intracellular TGF- 1, PAI-1 and Colla-
gen Type I mRNA expressions were significantly increased
by about 1.5, 1.5 and 1.5 fold by high glucose levels. Com-
pared with the high glucose and the transfection of TGF- 1
siRNAs (1, 2, and 4  g) TGF- 1, PAI-1 and Collagen Type
I mRNA levels were reduced in a dose-dependant manner.
In addition, the expression was significantly inhibited in
TGF- 1 siRNAs (4  g) treated .
G
r
o
w
t
h
 
I
n
d
e
x
 
(
O
D
 
a
t
 
4
1
5
 
n
m
) 1.2
0.8
0.4
0
N H 0.5X 1X 2X
Fig. 5. TGF- 1 siRNAs suppress high glucose-induced RMC
proliferation. RMCs transfected with TGF- 1 siRNAs were cul-
tured in medium containing normal glucose or high glucose for
24 hr, and the proliferation was determined by the WST-1 test. 
N: control (5.5 mM), H: stimulated with high glucose (30 mM), 0.5X:
0.1  g/ L TGF- 1 siRNAs transfection plus high glucose (30 mM)
stimulation for 24 hr. 1X: 0.2  g/ L TGF- 1 siRNAs transfection
plus high glucose (30 mM) stimulation for 24 hr. 2X: 0.4  g/ L
TGF- 1 siRNAs transfection plus high glucose (30 mM) stimula-
tion for 24 hr. 
Values are presented as means±SEM of triplicate experiments.
*p<0.05 compared to normal glucose; 
� p<0.05 compared to high
glucose.
*
*
�
TGF- 1
Fig. 3. The effect of TGF- 1 siRNAs on high glucose induced
TGF- 1, PAI-1 and Collagen Type I protein upregulation in RMCs
(Western blot). 
(A) Lane 1: control (5.5 mM), Lane 2: stimulated with high glucose
(30 mM), Lane 3: 2  g/ L TGF- 1 siRNAs transfection plus high
glucose (30 mM) stimulation for 24 hr. Lane 4: 4  g/ L TGF- 1
siRNAs transfection plus high glucose (30 mM) stimulation for 24
hr. Lane 5: 8  g/ L TGF- 1 siRNAs transfection plus high glucose
(30 mM) stimulation for 24 hr. (B) Values are presented as means
±SEM of triplicate experiments. *p<0.05 compared to normal
glucose; 
� p<0.05 compared to high glucose.
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Fig. 4. The effect of TGF- 1 siRNAs on the high glucose-induced
mRNA expression of TGF- 1, PAI-1 and Collagen Type I. RMCs
transfected with TGF- 1 siRNAs were cultured in medium contain-
ing 5.5 or 30 mM glucose for 24 hr and total RNA was extracted
from the RMCs. mRNA expression of TGF- 1, PAI-1 and Colla-
gen Type I was determined by RT-PCR (A). TGF- 1, PAI-1 and
Collagen Type I levels for each condition was measured by means
of an LAS-3000 image analyzer (B). 
Lane 1: control (5.5 mM), Lane 2: stimulated with high glucose (30
mM), Lane 3: 1  g/ L TGF- 1 siRNAs transfection plus high glu-
cose (30 mM) stimulation for 24 hr. Lane 4: 2  g/ L TGF- 1 siR-
NAs transfection plus high glucose (30 mM) stimulation for 24 hr.
Lane 5: 4  g/ L TGF- 1 siRNAs transfection plus high glucose
(30 mM) stimulation for 24 hr. 
Values are presented as means±SEM of triplicate experiments.
*p<0.05 compared to normal glucose; 
� p<0.05 compared to high
glucose.
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The effect of TGF- 1 siRNAs on RMCs proliferation
RMCs transfected with TGF- 1 siRNAs were cultured
in medium containing normal glucose or high glucose for
24 hr, and the proliferation was determined by the WST-1
test (Fig. 5). To examine the possibility of dose dependence
on the suppression effects of TGF- 1 siRNAs (0.1, 0.2 and
0.4  g) on the cell growth. They were transfected into pri-
mary cultured RMCs. Cell growth were significantly increased
by about 2.1 fold by high glucose levels. Compared with
the high glucose and the transfection of TGF- 1 siRNAs
(0.1, 0.2 and 0.4  g) cell growth were reduced in a dose-
dependant manner. In addition, the expression was signifi-
cantly inhibited in TGF- 1 siRNAs (0.4  g) treated .
DISCUSSION
Diabetic nephropathy is characterized by an expansion of
the glomerular mesangium, caused by mesangial cell prolif-
eration and an excessive accumulation of ECM proteins, even-
tually leading to glomerulosclerosis and renal failure. The
manifestation of diabetic nephropathy may be a consequence
of the actions of certain cytokines and growth factors. Promi-
nent among these is TGF- 1 because it promotes mesangial
cell expansion and stimulates ECM accumulation, in diabetic
renal disease (18).
TGF- 1 has been implicated as an etiologic cause in its
progression. TGF- 1 is a key mediator of the hyperglycemia-
induced panoramic effects on cell growth and ECM (19-21).
In addition, this cytokine has powerful fibrogenic potential
because of its capability for simultaneous actions such as the
stimulation of matrix synthesis, the inhibition of matrix degra-
dation, and the modulation of matrix receptor expression to
facilitate cell matrix interactions (22). High levels of glucose
increases TGF- 1 expression, and the cell expansion and mat-
rix-stimulatory effects of high glucose are prevented by anti-
TGF- 1 therapy. Thus, TGF- 1 is considered to be a ther-
apeutic target in diabetic nephropathy and other chronic kid-
ney diseases, and anti-TGF- 1 therapies have also been per-
formed (23-25).
The aim of gene therapy is to replace defective genes in tar-
get tissue by delivering correct versions of them in the form
of an expression vector. Recent progress in molecular biology
has provided new techniques to inhibit target gene expres-
sion. Gene therapies have been attempted by antisense ODN,
decoy, ribozyme, and RNAi. More recently, gene therapy using
RNAi as one of the anti-TGF- 1 therapies has been inves-
tigated and have been applied to renal disease. 
The TGF- 1 expression was increased by 1.8 fold in RMCs
stimulated by 30 mM glucose. In addition, they effectively
inhibited the expression of TGF- 1 mRNA and protein in
RMCs stimulated by 30 mM glucose. These results are con-
sistent with the notion that the transfection of TGF- 1 siR-
NAs is effective in reducing TGF- 1 expression. The pur-
pose of this study was to evaluate the efficiency of TGF- 1
siRNAs, to accomplish this fluorescein-labeled-TGF- 1 siR-
NAs were introduced into RMCs using the Mirus Transfer
IT. Fluorescence microscopy of RMCs that had been trans-
fected with Fluorescein- labeled-TGF- 1 siRNAs were ob-
served in both the nuclei and the cytoplasm. The effect of
TGF- 1 siRNAs on the endogenous gene expression of PAI-1
and Collagen Type I was also examined in RMCs. High glu-
cose levels significantly stimulates RMCs to increase the en-
dogenous translation of PAI-1 and Collagen Type I. The trans-
fection of RMCs with the TGF- 1 siRNAs resulted in a sig-
nificant attenuation of high glucose stimulation-induced gene
expression. This suggests that TGF- 1 siRNAs effectively
suppress the translation of endogenous genes that are involved
in ECM formation. High glucose levels significantly stimu-
late RMCs to increase the endogenous transcription of PAI-1
and Collagen Type I. The transfection of RMCs with the TGF-
1 siRNAs resulted in a significant attenuation of high glu-
cose stimulation-induced gene expression. This suggests that
TGF- 1 siRNAs effectively suppress the transcription of en-
dogenous genes that are involved in ECM formation (26-28).
To evaluate the influence of hyperglycemia on the prolifer-
ation of primary RMCs, we investigated the ability of TGF-
1 siRNAs to inhibit cell growth. High levels of glucose
significantly stimulated the growth of primary RMCs. The
transfection of RMCs with TGF- 1 siRNAs resulted in a
significant suppression of the cell growth stimulated by high
glucose. These results suggest that TGF- 1 siRNAs effec-
tively suppresses the proliferation of RMCs, as well as the
expression of genes that are involved in the accumulation of
ECM proteins. 
In summary, in this study, we applied TGF- 1 siRNAs
strategy to suppress TGF- 1 overexpression the cell prolif-
eration of RMCs induced by a high glucose concentrations.
The suppressive effect of TGF- 1 siRNAs was also applied
to the expression of PAI-1 and Collagen Type I which are
down-regulators of TGF- 1. Our results demonstrate that
TGF- 1 siRNAs efficiently suppressed the expression of
mesangium matrix component genes and inhibited high glu-
cose-induced mesangial cell proliferation. This siRNAs mech-
anism invented by nature to protect the genome provides us
with ideal tools to analyse gene function and for targeting
any transcript in any cell with a high efficiency and speci-
ficity. These findings suggest that TGF- 1 siRNAs may be
a useful tool for developing new therapeutic applications for
the prevention of progressive diabetic nephropathy. 
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